| Autor: |
Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., Reichman, R. C. |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; March 2000, Vol. 44 Issue: 3 p794-797, 4p |
| Abstrakt: |
ABSTRACTThe development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
